

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claims 1 to 4 (canceled).

Claim 5 (currently amended). A method for inhibiting a viral ~~microbial~~ infection in a cell, comprising contacting the cell with an imidazoquinoline compound or poly I:C to -a ~~molecule that stimulate[[s]]~~ induction of IRF3 in the cell, thereby inhibiting the viral ~~microbial~~ infection.

Claims 6 to 9 (canceled).

Claim 10 (currently amended). The method of claim 7, wherein the cell is ~~contacted with the molecule that stimulates the~~ TLR is a TLR ligand selected from a group consisting of a bacterial antigen, LPS, lipid A, taxol, a viral antigen, RSV F protein, double stranded RNA, imidazoquinoline compounds, and poly I:C.

Claims 11 to 19 (canceled).

Claim 20 (currently amended). A method for inhibiting viral replication in a cell by stimulating the TLR3/TLR4 and IRF3 pathways in the cell comprising contacting the cell with an imidazoquinoline compound or poly I:C ~~molecule that stimulates the TLR3/TLR4 and IRF3 pathways~~, thereby inhibiting the viral replication in the cell.

Claim 21 (currently amended). The method of claim 20, wherein the cell is ~~contacted with the molecule that stimulates the~~ TLR3/TLR4 and IRF3 pathways is a TLR ligand selected from a group consisting of bacterial antigen, LPS, lipid A, taxol, viral antigen, RSV F protein, double stranded RNA, imidazoquinoline compounds, and poly I:C.

Claims 22 to 24 (canceled).

Claim 25 (new).      The method of claim 5, wherein the cell is a macrophage.

Claim 26 (new).      The method of claim 20, wherein the cell is a macrophage.